Dr. Jiayong Liu 刘佳勇
Chief Physician, Associate Professor
Department of Bone and Soft Tissue Tumors, Peking University Cancer Hospital, Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Standardized and individualized treatment of soft tissue sarcomas, including systemic therapies. Surgical management of bone and soft tissue tumors, with expertise in vascular nerve handling and reconstruction. Surgery for cutaneous malignant melanoma.
Dr. Liu holds a medical doctorate from Peking University Health Science Center. Dr. Liu serves as Deputy Director and Chief Physician in the Department of Bone and Soft Tissue Tumors at Peking University Cancer Hospital.
Professional roles
- Standing Committee Member, Bone and Soft Tissue Tumor Branch, China Medical Education Association
- Standing Committee Member, Melanoma Professional Committee, Chinese Society of Clinical Oncology (CSCO)
- Vice Chair, Orthopedics Professional Committee, China Health Industry Association
- Deputy Editor-in-Chief, Chinese Expert Consensus on Surgical Diagnosis and Treatment of Cutaneous and Acral Malignant Melanoma
Name order: in Chinese the family name comes first (Liu Jiayong). Papers usually list the name as Jiayong Liu or Liu J.
Selected publications
38 papers on PubMed matched by name and affiliation; 17 as first or senior author since 2016. Most recent first- or senior-author papers:
- Clin Cancer Res, 2026 (senior author): Dual Inhibition of LAG-3 and PD-1 with IBI110 and Sintilimab in Advanced Alveolar Soft Part Sarcoma: A Single-Center, Phase II Trial. PubMed 42594032
- Cancers (Basel), 2026 (senior author): Lymphatic Mapping to the Inguinal Region in Patients with Lower Extremity Melanoma Undergoing Radical Inguinal Lymph Node Dissection: A Retrospective Cohort Study. PubMed 42882878
- World J Surg Oncol, 2026 (senior author): The efficacy and predictive value of (99m)Tc-rituximab for sentinel lymph node biopsy in acral melanoma patients. PubMed 42121159
- Cardiooncology, 2025 (senior author): Clinical characteristics and treatment outcomes of primary cardiac sarcomas: a retrospective analysis. PubMed 41299793
- Exp Hematol Oncol, 2025 (senior author): Superiority of targeted RNA sequencing for fusion detection and subtype diagnosis in Chinese sarcoma patients: a multicenter study. PubMed 40369594
- J Immunother Cancer, 2025 (senior author): Intratumoral oncolytic virus OH2 injection in patients with locally advanced or metastatic sarcoma: a phase 1/2 trial. PubMed 39824528
- Clin Cancer Res, 2024 (senior author): Anlotinib plus TQB2450, a PD-L1 Antibody, in Patients with Advanced Alveolar Soft Part Sarcoma: A Single-Arm, Phase II Trial. PubMed 39453774
- Signal Transduct Target Ther, 2024 (first author): Neoadjuvant oncolytic virus orienx010 and toripalimab in resectable acral melanoma: a phase Ib trial. PubMed 39572525
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion